What ||| S:0 E:4 ||| WP
's  ||| S:4 E:7 ||| VBZ
new  ||| S:7 E:11 ||| JJ
in  ||| S:11 E:14 ||| IN
dermato-oncology ||| S:14 E:30 ||| JJ
?  ||| S:30 E:32 ||| .
One  ||| S:32 E:36 ||| CD
of  ||| S:36 E:39 ||| IN
the  ||| S:39 E:43 ||| DT
major  ||| S:43 E:49 ||| JJ
advance  ||| S:49 E:57 ||| NN
concerning  ||| S:57 E:68 ||| VBG
skin  ||| S:68 E:73 ||| NN
carcinoma  ||| S:73 E:83 ||| NN
is  ||| S:83 E:86 ||| VBZ
the  ||| S:86 E:90 ||| DT
development  ||| S:90 E:102 ||| NN
of  ||| S:102 E:105 ||| IN
targeted  ||| S:105 E:114 ||| JJ
therapy ||| S:114 E:121 ||| NN
:  ||| S:121 E:123 ||| :
anti-patch ||| S:123 E:133 ||| FW
/ ||| S:133 E:134 ||| FW
sonic ||| S:134 E:139 ||| FW
/ ||| S:139 E:140 ||| FW
hedgehog  ||| S:140 E:149 ||| FW
for  ||| S:149 E:153 ||| FW
basal  ||| S:153 E:159 ||| FW
cell  ||| S:159 E:164 ||| FW
carcinoma  ||| S:164 E:174 ||| FW
( ||| S:174 E:175 ||| -LRB-
BCC ||| S:175 E:178 ||| NNP
)  ||| S:178 E:180 ||| -RRB-
and  ||| S:180 E:184 ||| CC
anti-EGFR  ||| S:184 E:194 ||| JJ
for  ||| S:194 E:198 ||| IN
squamous  ||| S:198 E:207 ||| JJ
cell  ||| S:207 E:212 ||| NN
carcinoma  ||| S:212 E:222 ||| NNS
( ||| S:222 E:223 ||| -LRB-
SCC ||| S:223 E:226 ||| NNP
) ||| S:226 E:227 ||| -RRB-
.  ||| S:227 E:229 ||| .
These  ||| S:229 E:235 ||| DT
therapies  ||| S:235 E:245 ||| NNS
are  ||| S:245 E:249 ||| VBP
indicated  ||| S:249 E:259 ||| VBN
for  ||| S:259 E:263 ||| IN
advanced  ||| S:263 E:272 ||| JJ
non  ||| S:272 E:276 ||| NNS
surgically  ||| S:276 E:287 ||| RB
removable  ||| S:287 E:297 ||| JJ
tumors ||| S:297 E:303 ||| NNS
.  ||| S:303 E:305 ||| .
Their  ||| S:305 E:311 ||| PRP$
anti-tumoral  ||| S:311 E:324 ||| JJ
efficacy  ||| S:324 E:333 ||| NN
has  ||| S:333 E:337 ||| VBZ
been  ||| S:337 E:342 ||| VBN
shown ||| S:342 E:347 ||| VBN
,  ||| S:347 E:349 ||| ,
their  ||| S:349 E:355 ||| PRP$
effect  ||| S:355 E:362 ||| NN
seems  ||| S:362 E:368 ||| VBZ
to  ||| S:368 E:371 ||| TO
be  ||| S:371 E:374 ||| VB
suspensive  ||| S:374 E:385 ||| NNS
which  ||| S:385 E:391 ||| WDT
raises  ||| S:391 E:398 ||| VBZ
the  ||| S:398 E:402 ||| DT
question  ||| S:402 E:411 ||| NN
of  ||| S:411 E:414 ||| IN
their  ||| S:414 E:420 ||| PRP$
tolerability  ||| S:420 E:433 ||| NN
for  ||| S:433 E:437 ||| IN
long  ||| S:437 E:442 ||| JJ
term  ||| S:442 E:447 ||| NN
use ||| S:447 E:450 ||| NN
.  ||| S:450 E:452 ||| .
Laboratory  ||| S:452 E:463 ||| NNP
work  ||| S:463 E:468 ||| NN
have  ||| S:468 E:473 ||| VBP
shown  ||| S:473 E:479 ||| VBN
that  ||| S:479 E:484 ||| IN
BCC  ||| S:484 E:488 ||| NNP
and  ||| S:488 E:492 ||| CC
SCC  ||| S:492 E:496 ||| NNP
stem  ||| S:496 E:501 ||| NN
cells  ||| S:501 E:507 ||| NNS
locate  ||| S:507 E:514 ||| VBP
in  ||| S:514 E:517 ||| IN
different  ||| S:517 E:527 ||| JJ
cell  ||| S:527 E:532 ||| NN
compartments  ||| S:532 E:545 ||| NNS
and  ||| S:545 E:549 ||| CC
follow  ||| S:549 E:556 ||| VB
distinct  ||| S:556 E:565 ||| JJ
molecular  ||| S:565 E:575 ||| JJ
events  ||| S:575 E:582 ||| NNS
which  ||| S:582 E:588 ||| WDT
explains  ||| S:588 E:597 ||| VBZ
their  ||| S:597 E:603 ||| PRP$
distinct  ||| S:603 E:612 ||| JJ
behaviour ||| S:612 E:621 ||| NN
.  ||| S:621 E:623 ||| .
The  ||| S:623 E:627 ||| DT
role  ||| S:627 E:632 ||| NN
of  ||| S:632 E:635 ||| IN
HPV  ||| S:635 E:639 ||| NNP
in  ||| S:639 E:642 ||| IN
EBDR  ||| S:642 E:647 ||| NNP
skin  ||| S:647 E:652 ||| NN
cancers  ||| S:652 E:660 ||| NNS
has  ||| S:660 E:664 ||| VBZ
been  ||| S:664 E:669 ||| VBN
ruled  ||| S:669 E:675 ||| VBN
out ||| S:675 E:678 ||| RP
.  ||| S:678 E:680 ||| .
Photodynamic  ||| S:680 E:693 ||| JJ
therapy  ||| S:693 E:701 ||| NN
induced-immunosuppression  ||| S:701 E:727 ||| NN
can  ||| S:727 E:731 ||| MD
be  ||| S:731 E:734 ||| VB
prevented  ||| S:734 E:744 ||| VBN
by  ||| S:744 E:747 ||| IN
lowering  ||| S:747 E:756 ||| VBG
the  ||| S:756 E:760 ||| DT
light  ||| S:760 E:766 ||| JJ
fluence ||| S:766 E:773 ||| NN
.  ||| S:773 E:775 ||| .
The  ||| S:775 E:779 ||| DT
gene  ||| S:779 E:784 ||| NN
responsible  ||| S:784 E:796 ||| JJ
for  ||| S:796 E:800 ||| IN
the  ||| S:800 E:804 ||| DT
Ferguson  ||| S:804 E:813 ||| NNP
Smith  ||| S:813 E:819 ||| NNP
syndrome  ||| S:819 E:828 ||| NN
has  ||| S:828 E:832 ||| VBZ
been  ||| S:832 E:837 ||| VBN
identified ||| S:837 E:847 ||| VBN
:  ||| S:847 E:849 ||| :
it  ||| S:849 E:852 ||| PRP
is  ||| S:852 E:855 ||| VBZ
the  ||| S:855 E:859 ||| DT
gene  ||| S:859 E:864 ||| NN
encoding  ||| S:864 E:873 ||| VBD
TGFBR1 ||| S:873 E:879 ||| CD
.  ||| S:879 E:881 ||| .
Its  ||| S:881 E:885 ||| PRP$
implication  ||| S:885 E:897 ||| NN
in  ||| S:897 E:900 ||| IN
SCC  ||| S:900 E:904 ||| NNP
needs  ||| S:904 E:910 ||| VBZ
to  ||| S:910 E:913 ||| TO
be  ||| S:913 E:916 ||| VB
determined ||| S:916 E:926 ||| VBN
.  ||| S:926 E:928 ||| .
A  ||| S:928 E:930 ||| DT
new  ||| S:930 E:934 ||| JJ
compound ||| S:934 E:942 ||| NN
,  ||| S:942 E:944 ||| ,
PEP005 ||| S:944 E:950 ||| NNP
,  ||| S:950 E:952 ||| ,
( ||| S:952 E:953 ||| -LRB-
ingenol  ||| S:953 E:961 ||| FW
mebutate ||| S:961 E:969 ||| FW
)  ||| S:969 E:971 ||| -RRB-
should  ||| S:971 E:978 ||| MD
soon  ||| S:978 E:983 ||| RB
enlarge  ||| S:983 E:991 ||| VB
therapeutical  ||| S:991 E:1005 ||| JJ
options  ||| S:1005 E:1013 ||| NNS
for  ||| S:1013 E:1017 ||| IN
actinic  ||| S:1017 E:1025 ||| JJ
keratosis ||| S:1025 E:1034 ||| NN
.  ||| S:1034 E:1036 ||| .
Concerning  ||| S:1036 E:1047 ||| VBG
melanoma ||| S:1047 E:1055 ||| NN
,  ||| S:1055 E:1057 ||| ,
results  ||| S:1057 E:1065 ||| NNS
of  ||| S:1065 E:1068 ||| IN
the  ||| S:1068 E:1072 ||| DT
two  ||| S:1072 E:1076 ||| CD
phase  ||| S:1076 E:1082 ||| NN
III  ||| S:1082 E:1086 ||| NNP
studies  ||| S:1086 E:1094 ||| NNS
using  ||| S:1094 E:1100 ||| VBG
two  ||| S:1100 E:1104 ||| CD
innovative  ||| S:1104 E:1115 ||| JJ
therapies  ||| S:1115 E:1125 ||| NNS
( ||| S:1125 E:1126 ||| -LRB-
anti-Braf  ||| S:1126 E:1136 ||| NNP
and  ||| S:1136 E:1140 ||| CC
ipilimumab ||| S:1140 E:1150 ||| CD
)  ||| S:1150 E:1152 ||| -RRB-
have  ||| S:1152 E:1157 ||| VBP
been  ||| S:1157 E:1162 ||| VBN
published ||| S:1162 E:1171 ||| VBN
.  ||| S:1171 E:1173 ||| .
Comparative  ||| S:1173 E:1185 ||| JJ
study  ||| S:1185 E:1191 ||| NN
between  ||| S:1191 E:1199 ||| IN
anti-Braf  ||| S:1199 E:1209 ||| JJ
and  ||| S:1209 E:1213 ||| CC
DTIC  ||| S:1213 E:1218 ||| NNP
has  ||| S:1218 E:1222 ||| VBZ
shown  ||| S:1222 E:1228 ||| VBN
a  ||| S:1228 E:1230 ||| DT
response  ||| S:1230 E:1239 ||| NN
rate  ||| S:1239 E:1244 ||| NN
of  ||| S:1244 E:1247 ||| IN
48.4  ||| S:1247 E:1252 ||| CD
%  ||| S:1252 E:1254 ||| NN
with  ||| S:1254 E:1259 ||| IN
vemurafenib  ||| S:1259 E:1271 ||| NN
and  ||| S:1271 E:1275 ||| CC
5.5  ||| S:1275 E:1279 ||| CD
%  ||| S:1279 E:1281 ||| NN
with  ||| S:1281 E:1286 ||| IN
DTIC ||| S:1286 E:1290 ||| NNP
.  ||| S:1290 E:1292 ||| .
The  ||| S:1292 E:1296 ||| DT
risk  ||| S:1296 E:1301 ||| NN
of  ||| S:1301 E:1304 ||| IN
death  ||| S:1304 E:1310 ||| NN
was  ||| S:1310 E:1314 ||| VBD
diminished  ||| S:1314 E:1325 ||| VBN
by  ||| S:1325 E:1328 ||| IN
67  ||| S:1328 E:1331 ||| CD
% ||| S:1331 E:1332 ||| NN
.  ||| S:1332 E:1334 ||| .
These  ||| S:1334 E:1340 ||| DT
results  ||| S:1340 E:1348 ||| NNS
have  ||| S:1348 E:1353 ||| VBP
allowed  ||| S:1353 E:1361 ||| VBN
to  ||| S:1361 E:1364 ||| TO
switch  ||| S:1364 E:1371 ||| VB
to  ||| S:1371 E:1374 ||| TO
vemurafenib  ||| S:1374 E:1386 ||| VB
patients  ||| S:1386 E:1395 ||| NNS
with  ||| S:1395 E:1400 ||| IN
progression  ||| S:1400 E:1412 ||| NN
under  ||| S:1412 E:1418 ||| IN
DTIC ||| S:1418 E:1422 ||| NNP
.  ||| S:1422 E:1424 ||| .
However ||| S:1424 E:1431 ||| RB
,  ||| S:1431 E:1433 ||| ,
the  ||| S:1433 E:1437 ||| DT
initial  ||| S:1437 E:1445 ||| JJ
response  ||| S:1445 E:1454 ||| NN
is  ||| S:1454 E:1457 ||| VBZ
followed  ||| S:1457 E:1466 ||| VBN
by  ||| S:1466 E:1469 ||| IN
relapse  ||| S:1469 E:1477 ||| NN
in  ||| S:1477 E:1480 ||| IN
a  ||| S:1480 E:1482 ||| DT
majority  ||| S:1482 E:1491 ||| NN
of  ||| S:1491 E:1494 ||| IN
cases ||| S:1494 E:1499 ||| NNS
.  ||| S:1499 E:1501 ||| .
Mechanisms  ||| S:1501 E:1512 ||| NNS
of  ||| S:1512 E:1515 ||| IN
this  ||| S:1515 E:1520 ||| DT
resistance  ||| S:1520 E:1531 ||| NN
have  ||| S:1531 E:1536 ||| VBP
been  ||| S:1536 E:1541 ||| VBN
studied  ||| S:1541 E:1549 ||| VBN
and  ||| S:1549 E:1553 ||| CC
the  ||| S:1553 E:1557 ||| DT
inhibition  ||| S:1557 E:1568 ||| NN
of  ||| S:1568 E:1571 ||| IN
several  ||| S:1571 E:1579 ||| JJ
molecules  ||| S:1579 E:1589 ||| NNS
involved  ||| S:1589 E:1598 ||| VBN
in  ||| S:1598 E:1601 ||| IN
different  ||| S:1601 E:1611 ||| JJ
or  ||| S:1611 E:1614 ||| CC
identical  ||| S:1614 E:1624 ||| JJ
pathway  ||| S:1624 E:1632 ||| NN
should  ||| S:1632 E:1639 ||| MD
help  ||| S:1639 E:1644 ||| VB
to  ||| S:1644 E:1647 ||| TO
resolve  ||| S:1647 E:1655 ||| VB
that  ||| S:1655 E:1660 ||| DT
problem ||| S:1660 E:1667 ||| NN
.  ||| S:1667 E:1669 ||| .
The  ||| S:1669 E:1673 ||| DT
combination  ||| S:1673 E:1685 ||| NN
ipilimumab+  ||| S:1685 E:1697 ||| NNP
DTIC  ||| S:1697 E:1702 ||| NNP
gives  ||| S:1702 E:1708 ||| VBZ
better  ||| S:1708 E:1715 ||| JJR
results  ||| S:1715 E:1723 ||| NNS
than  ||| S:1723 E:1728 ||| IN
DTIC  ||| S:1728 E:1733 ||| NNP
alone ||| S:1733 E:1738 ||| RB
.  ||| S:1738 E:1740 ||| .
The  ||| S:1740 E:1744 ||| DT
adverse  ||| S:1744 E:1752 ||| JJ
events  ||| S:1752 E:1759 ||| NNS
of  ||| S:1759 E:1762 ||| IN
this  ||| S:1762 E:1767 ||| DT
association  ||| S:1767 E:1779 ||| NN
are  ||| S:1779 E:1783 ||| VBP
slightly  ||| S:1783 E:1792 ||| RB
different  ||| S:1792 E:1802 ||| JJ
than  ||| S:1802 E:1807 ||| IN
those  ||| S:1807 E:1813 ||| DT
seen  ||| S:1813 E:1818 ||| VBN
with  ||| S:1818 E:1823 ||| IN
ipilimumab  ||| S:1823 E:1834 ||| VBG
alone ||| S:1834 E:1839 ||| RB
.  ||| S:1839 E:1841 ||| .
They  ||| S:1841 E:1846 ||| PRP
must  ||| S:1846 E:1851 ||| MD
be  ||| S:1851 E:1854 ||| VB
known  ||| S:1854 E:1860 ||| VBN
by  ||| S:1860 E:1863 ||| IN
prescribers ||| S:1863 E:1874 ||| NN
.  ||| S:1874 E:1876 ||| .
Some  ||| S:1876 E:1881 ||| DT
discussions  ||| S:1881 E:1893 ||| NNS
are  ||| S:1893 E:1897 ||| VBP
on  ||| S:1897 E:1900 ||| IN
their  ||| S:1900 E:1906 ||| PRP$
way  ||| S:1906 E:1910 ||| NN
between  ||| S:1910 E:1918 ||| IN
the  ||| S:1918 E:1922 ||| DT
two  ||| S:1922 E:1926 ||| CD
companies  ||| S:1926 E:1936 ||| NNS
developping  ||| S:1936 E:1948 ||| VBP
anti-Braf  ||| S:1948 E:1958 ||| JJ
and  ||| S:1958 E:1962 ||| CC
ipilimumab  ||| S:1962 E:1973 ||| JJ
to  ||| S:1973 E:1976 ||| TO
develop  ||| S:1976 E:1984 ||| VB
therapeutic  ||| S:1984 E:1996 ||| JJ
strategies  ||| S:1996 E:2007 ||| NNS
combining  ||| S:2007 E:2017 ||| VBG
both  ||| S:2017 E:2022 ||| DT
treatments.  ||| S:2022 E:2034 ||| CD
20  ||| S:2034 E:2037 ||| CD
to  ||| S:2037 E:2040 ||| TO
30  ||| S:2040 E:2043 ||| CD
%  ||| S:2043 E:2045 ||| NN
of  ||| S:2045 E:2048 ||| IN
patients  ||| S:2048 E:2057 ||| NNS
taking  ||| S:2057 E:2064 ||| VBG
anti-Braf  ||| S:2064 E:2074 ||| JJ
drugs  ||| S:2074 E:2080 ||| NNS
will  ||| S:2080 E:2085 ||| MD
develop  ||| S:2085 E:2093 ||| VB
SCC  ||| S:2093 E:2097 ||| NNP
( ||| S:2097 E:2098 ||| -LRB-
due  ||| S:2098 E:2102 ||| JJ
to  ||| S:2102 E:2105 ||| TO
paradoxal  ||| S:2105 E:2115 ||| VB
activation  ||| S:2115 E:2126 ||| VBN
of  ||| S:2126 E:2129 ||| IN
MAPK  ||| S:2129 E:2134 ||| NNP
in  ||| S:2134 E:2137 ||| IN
non  ||| S:2137 E:2141 ||| FW
Braf  ||| S:2141 E:2146 ||| FW
mutated  ||| S:2146 E:2154 ||| FW
cells ||| S:2154 E:2159 ||| FW
) ||| S:2159 E:2160 ||| -RRB-
.  ||| S:2160 E:2162 ||| .
PEG-interferon  ||| S:2162 E:2177 ||| NNP
seems  ||| S:2177 E:2183 ||| VBZ
to  ||| S:2183 E:2186 ||| TO
be  ||| S:2186 E:2189 ||| VB
indicated  ||| S:2189 E:2199 ||| VBN
in  ||| S:2199 E:2202 ||| IN
ulcerated  ||| S:2202 E:2212 ||| JJ
melanoma  ||| S:2212 E:2221 ||| NN
with  ||| S:2221 E:2226 ||| IN
lymph  ||| S:2226 E:2232 ||| JJ
node  ||| S:2232 E:2237 ||| JJ
micrometastasis ||| S:2237 E:2252 ||| NN
.  ||| S:2252 E:2254 ||| .
Some  ||| S:2254 E:2259 ||| DT
other  ||| S:2259 E:2265 ||| JJ
targeted  ||| S:2265 E:2274 ||| JJ
molecules  ||| S:2274 E:2284 ||| NNS
such  ||| S:2284 E:2289 ||| JJ
as  ||| S:2289 E:2292 ||| IN
C-KIT  ||| S:2292 E:2298 ||| JJ
and  ||| S:2298 E:2302 ||| CC
anti-MEK  ||| S:2302 E:2311 ||| NNS
are  ||| S:2311 E:2315 ||| VBP
under  ||| S:2315 E:2321 ||| IN
evaluation ||| S:2321 E:2331 ||| NN
.  ||| S:2331 E:2333 ||| .
The  ||| S:2333 E:2337 ||| DT
effect  ||| S:2337 E:2344 ||| NN
of  ||| S:2344 E:2347 ||| IN
sunscreens  ||| S:2347 E:2358 ||| NN
on  ||| S:2358 E:2361 ||| IN
melanoma  ||| S:2361 E:2370 ||| JJ
risk  ||| S:2370 E:2375 ||| NN
prevention  ||| S:2375 E:2386 ||| NN
has  ||| S:2386 E:2390 ||| VBZ
been  ||| S:2390 E:2395 ||| VBN
reported  ||| S:2395 E:2404 ||| VBN
in  ||| S:2404 E:2407 ||| IN
an  ||| S:2407 E:2410 ||| DT
Australian  ||| S:2410 E:2421 ||| JJ
study ||| S:2421 E:2426 ||| NN
.  ||| S:2426 E:2428 ||| .
A  ||| S:2428 E:2430 ||| DT
low  ||| S:2430 E:2434 ||| JJ
vitamine  ||| S:2434 E:2443 ||| JJ
D  ||| S:2443 E:2445 ||| NNP
status  ||| S:2445 E:2452 ||| NN
is  ||| S:2452 E:2455 ||| VBZ
reported  ||| S:2455 E:2464 ||| VBN
to  ||| S:2464 E:2467 ||| TO
have  ||| S:2467 E:2472 ||| VB
a  ||| S:2472 E:2474 ||| DT
bad  ||| S:2474 E:2478 ||| JJ
prognosis  ||| S:2478 E:2488 ||| NN
in  ||| S:2488 E:2491 ||| IN
melanoma  ||| S:2491 E:2500 ||| NN
and  ||| S:2500 E:2504 ||| CC
is  ||| S:2504 E:2507 ||| VBZ
observed  ||| S:2507 E:2516 ||| VBN
in  ||| S:2516 E:2519 ||| IN
fair  ||| S:2519 E:2524 ||| JJ
skin  ||| S:2524 E:2529 ||| NN
patients  ||| S:2529 E:2538 ||| NNS
at  ||| S:2538 E:2541 ||| IN
risk ||| S:2541 E:2545 ||| NN
.  ||| S:2545 E:2547 ||| .
Recommendations  ||| S:2547 E:2563 ||| NNS
for  ||| S:2563 E:2567 ||| IN
the  ||| S:2567 E:2571 ||| DT
care  ||| S:2571 E:2576 ||| NN
and  ||| S:2576 E:2580 ||| CC
follow  ||| S:2580 E:2587 ||| VB
up  ||| S:2587 E:2590 ||| RP
of  ||| S:2590 E:2593 ||| IN
patients  ||| S:2593 E:2602 ||| NNS
with  ||| S:2602 E:2607 ||| IN
Merkel  ||| S:2607 E:2614 ||| NNP
carcinoma  ||| S:2614 E:2624 ||| NNS
have  ||| S:2624 E:2629 ||| VBP
been  ||| S:2629 E:2634 ||| VBN
published ||| S:2634 E:2643 ||| VBN
.  ||| S:2643 E:2645 ||| .
The  ||| S:2645 E:2649 ||| DT
elevated  ||| S:2649 E:2658 ||| JJ
risk  ||| S:2658 E:2663 ||| NN
of  ||| S:2663 E:2666 ||| IN
positive  ||| S:2666 E:2675 ||| JJ
sentinel  ||| S:2675 E:2684 ||| JJ
lymph  ||| S:2684 E:2690 ||| JJ
nodes  ||| S:2690 E:2696 ||| NN
in  ||| S:2696 E:2699 ||| IN
these  ||| S:2699 E:2705 ||| DT
patients  ||| S:2705 E:2714 ||| NNS
does  ||| S:2714 E:2719 ||| VBZ
not  ||| S:2719 E:2723 ||| RB
allow  ||| S:2723 E:2729 ||| VB
to  ||| S:2729 E:2732 ||| TO
define  ||| S:2732 E:2739 ||| VB
a  ||| S:2739 E:2741 ||| DT
subgroup  ||| S:2741 E:2750 ||| NN
of  ||| S:2750 E:2753 ||| IN
Merkel  ||| S:2753 E:2760 ||| NNP
patients  ||| S:2760 E:2769 ||| NNS
that  ||| S:2769 E:2774 ||| WDT
could  ||| S:2774 E:2780 ||| MD
be  ||| S:2780 E:2783 ||| VB
spared  ||| S:2783 E:2790 ||| VBN
from  ||| S:2790 E:2795 ||| IN
the  ||| S:2795 E:2799 ||| DT
technique ||| S:2799 E:2808 ||| NN
.  ||| S:2808 E:2810 ||| .
Sarcoma  ||| S:2810 E:2818 ||| NNP
also  ||| S:2818 E:2823 ||| RB
benefit  ||| S:2823 E:2831 ||| VB
from  ||| S:2831 E:2836 ||| IN
targeted  ||| S:2836 E:2845 ||| JJ
therapy  ||| S:2845 E:2853 ||| NN
especially  ||| S:2853 E:2864 ||| RB
DFSP  ||| S:2864 E:2869 ||| VBN
with  ||| S:2869 E:2874 ||| IN
imatinib ||| S:2874 E:2882 ||| NN
.  ||| S:2882 E:2884 ||| .
Other  ||| S:2884 E:2890 ||| JJ
molecules  ||| S:2890 E:2900 ||| NNS
among  ||| S:2900 E:2906 ||| IN
which  ||| S:2906 E:2912 ||| WDT
mTOR  ||| S:2912 E:2917 ||| JJ
inhibitors  ||| S:2917 E:2928 ||| NNS
are  ||| S:2928 E:2932 ||| VBP
being  ||| S:2932 E:2938 ||| VBG
evaluated  ||| S:2938 E:2948 ||| VBN
in  ||| S:2948 E:2951 ||| IN
sarcomas ||| S:2951 E:2959 ||| NN
.  ||| S:2959 E:2961 ||| .
A  ||| S:2961 E:2963 ||| DT
collaborative  ||| S:2963 E:2977 ||| JJ
work  ||| S:2977 E:2982 ||| NN
has  ||| S:2982 E:2986 ||| VBZ
allowed  ||| S:2986 E:2994 ||| VBN
to  ||| S:2994 E:2997 ||| TO
classify  ||| S:2997 E:3006 ||| VB
and  ||| S:3006 E:3010 ||| CC
evaluate  ||| S:3010 E:3019 ||| VB
in  ||| S:3019 E:3022 ||| IN
a  ||| S:3022 E:3024 ||| DT
more  ||| S:3024 E:3029 ||| RBR
standardized  ||| S:3029 E:3042 ||| JJ
way  ||| S:3042 E:3046 ||| NN
cutaneous  ||| S:3046 E:3056 ||| NN
T  ||| S:3056 E:3058 ||| NN
lymphomas  ||| S:3058 E:3068 ||| NNS
and  ||| S:3068 E:3072 ||| CC
should  ||| S:3072 E:3079 ||| MD
help  ||| S:3079 E:3084 ||| VB
future  ||| S:3084 E:3091 ||| JJ
trials ||| S:3091 E:3097 ||| NNS
.  ||| S:3097 E:3099 ||| .
Some  ||| S:3099 E:3104 ||| DT
microRNA  ||| S:3104 E:3113 ||| NN
can  ||| S:3113 E:3117 ||| MD
be  ||| S:3117 E:3120 ||| VB
used  ||| S:3120 E:3125 ||| VBN
as  ||| S:3125 E:3128 ||| IN
diagnostic  ||| S:3128 E:3139 ||| JJ
tools  ||| S:3139 E:3145 ||| NNS
or  ||| S:3145 E:3148 ||| CC
therapies  ||| S:3148 E:3158 ||| NNS
in  ||| S:3158 E:3161 ||| IN
T  ||| S:3161 E:3163 ||| NN
cell  ||| S:3163 E:3168 ||| NN
cutaneous  ||| S:3168 E:3178 ||| NN
lymphomas ||| S:3178 E:3187 ||| NN
.  ||| S:3187 E:3189 ||| .
Finally  ||| S:3189 E:3197 ||| RB
a  ||| S:3197 E:3199 ||| DT
review  ||| S:3199 E:3206 ||| NN
of  ||| S:3206 E:3209 ||| IN
modern  ||| S:3209 E:3216 ||| JJ
therapeutical  ||| S:3216 E:3230 ||| JJ
strategies  ||| S:3230 E:3241 ||| NNS
in  ||| S:3241 E:3244 ||| IN
cutaneous  ||| S:3244 E:3254 ||| JJ
lymphomas  ||| S:3254 E:3264 ||| NN
has  ||| S:3264 E:3268 ||| VBZ
been  ||| S:3268 E:3273 ||| VBN
published ||| S:3273 E:3282 ||| VBN
.  ||| S:3282 E:3284 ||| .
